Your browser is no longer supported. Please, upgrade your browser.
ESPR Esperion Therapeutics, Inc. daily Stock Chart
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-9.63 Insider Own0.90% Shs Outstand27.52M Perf Week-8.46%
Market Cap1.04B Forward P/E- EPS next Y-7.17 Insider Trans3.06% Shs Float27.35M Perf Month-27.51%
Income-262.80M PEG- EPS next Q1.71 Inst Own- Short Float38.33% Perf Quarter-23.36%
Sales4.80M P/S216.06 EPS this Y52.50% Inst Trans-0.03% Short Ratio15.60 Perf Half Y-43.96%
Book/sh-1.83 P/B- EPS next Y-40.60% ROA-109.70% Target Price- Perf Year-1.88%
Cash/sh5.61 P/C6.59 EPS next 5Y28.30% ROE-627.40% 52W Range24.82 - 76.98 Perf YTD-37.95%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-467.80% 52W High-51.94% Beta1.90
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin99.40% 52W Low49.07% ATR2.22
Employees193 Current Ratio2.40 Sales Q/Q-98.80% Oper. Margin- RSI (14)33.73 Volatility4.65% 5.45%
OptionableYes Debt/Eq- EPS Q/Q-192.60% Profit Margin- Rel Volume1.44 Prev Close38.00
ShortableYes LT Debt/Eq- EarningsAug 10 AMC Payout- Avg Volume672.00K Price37.00
Recom1.60 SMA20-13.49% SMA50-17.88% SMA200-21.23% Volume966,953 Change-2.63%
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Aug-10-20 05:15PM  
Aug-07-20 09:27AM  
Aug-06-20 10:05AM  
Aug-03-20 07:26AM  
Jul-16-20 07:16PM  
Jul-01-20 11:12AM  
Jun-23-20 11:42AM  
Jun-22-20 07:00AM  
Jun-16-20 03:09PM  
Jun-14-20 09:30AM  
Jun-12-20 10:20AM  
Jun-08-20 08:00AM  
Jun-05-20 11:31AM  
Jun-04-20 12:00PM  
May-27-20 08:00AM  
May-15-20 06:00PM  
May-08-20 02:49PM  
May-07-20 11:47AM  
May-06-20 06:55PM  
Apr-30-20 08:00AM  
Apr-21-20 07:01AM  
Apr-20-20 07:00AM  
Apr-18-20 10:59AM  
Apr-09-20 08:00AM  
Apr-07-20 10:43AM  
Apr-06-20 07:05AM  
Apr-05-20 08:26AM  
Mar-30-20 04:15PM  
Mar-28-20 11:30AM  
Mar-23-20 07:30AM  
Mar-18-20 07:30AM  
Feb-28-20 04:15PM  
Feb-27-20 10:15AM  
Feb-26-20 05:30PM  
Feb-21-20 04:38PM  
Feb-16-20 03:03PM  
Feb-03-20 01:30PM  
Jan-31-20 07:02AM  
Jan-27-20 12:20PM  
Jan-07-20 07:30AM  
Jan-03-20 04:15PM  
Dec-12-19 11:59AM  
Dec-06-19 11:31AM  
Nov-28-19 07:09AM  
Nov-22-19 06:30PM  
Nov-19-19 09:13AM  
Nov-17-19 03:05PM  
Nov-12-19 11:05AM  
Nov-10-19 07:56AM  
Nov-09-19 09:26AM  
Nov-07-19 11:04AM  
Nov-06-19 08:45AM  
Nov-04-19 07:30AM  
Oct-29-19 07:30AM  
Oct-28-19 05:15PM  
Oct-25-19 10:00AM  
Oct-04-19 08:34AM  
Sep-09-19 10:57AM  
Sep-07-19 09:30AM  
Sep-06-19 06:15PM  
Aug-30-19 04:15PM  
Aug-29-19 07:30AM  
Aug-26-19 11:05AM  
Aug-20-19 11:15AM  
Aug-09-19 08:06AM  
Aug-08-19 09:15AM  
Aug-06-19 04:15PM  
Aug-02-19 07:15PM  
Jul-31-19 01:48PM  
Jul-30-19 04:15PM  
Jul-29-19 08:08AM  
Jul-07-19 07:10PM  
Jul-05-19 12:25PM  
Jun-26-19 04:10PM  
Jun-19-19 10:40AM  
Jun-07-19 09:30AM  
May-30-19 04:15PM  
May-29-19 04:23PM  
May-28-19 07:00AM  
May-27-19 06:00AM  
May-10-19 08:00AM  
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAYLEBEN TIMOTHY MPresident & CEOMar 11Buy43.002,500107,500111,998Mar 12 07:34 AM
MAYLEBEN TIMOTHY MPresident & CEOFeb 28Buy49.005,000245,000109,498Mar 02 06:16 AM
BIOTECH TARGET N V10% OwnerJan 23Buy52.1220,0001,042,3983,747,964Jan 27 12:51 PM
MAYLEBEN TIMOTHY MPresident & CEONov 06Buy36.985,000184,90083,663Nov 08 04:14 PM
BIOTECH TARGET N V10% OwnerNov 06Buy37.3075,0002,797,5603,727,964Nov 08 02:54 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 06Buy35.252,50088,12578,663Sep 06 04:22 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 04Buy34.205,000170,98276,163Sep 06 04:22 PM
BIOTECH TARGET N V10% OwnerSep 04Buy33.7880,0002,702,2083,652,964Sep 06 04:09 PM